Cepheid, Inc. (CPHD) Misses Q2 EPS by 1c; Guides

Cepheid, Inc. (NASDAQ: CPHD) reported Q2 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $116.5 million versus the consensus estimate of $115.47 million.

Cepheid, Inc. sees FY2014 EPS of $0.10-$0.13, which may note compare to the consensus of ($0.37). Cepheid, Inc. sees FY2014 revenue of $452-461 million, versus the consensus of $460.13 million.

"With continuing adoption of our GeneXpert system in both commercial and emerging HBDC geographies, we placed a record 1,084 GeneXpert systems in the quarter, more systems than we placed in all of 2012," said John Bishop, Cepheid's Chairman and Chief Executive Officer. "Furthermore, we continued to execute well on Xpert® test menu expansion, making Xpert HPV, Xpert Norovirus and Xpert Carba-R available for the first time to our international customers during the quarter, bringing the total number of tests available to 17."

For earnings history and earnings-related data on Cepheid, Inc. (CPHD) click here.

You May Also Be Interested In

• Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
• Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
• American Express (AXP) down despite beating Q1 estimates on top and bottom lines